Showing 1761-1770 of 2152 results for "".
- Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing Iluvien in Benelux Countrieshttps://modernod.com/news/alimera-announces-expansion-of-agreement-with-distribution-partner-horus-pharma-to-include-marketing-iluvien-in-benelux-countries/2476878/Alimera Sciences announced that it has expanded its relationship with Horus Pharma, one of the company’s current distributors of Iluvien in Europe. Following the successful launch of Iluvien for diabetic macular edema (DME) in France by Horus Pharma, Alimera Sciences and Horus have agreed to expa
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- Acuity Eyecare Group Enters Texas Market With Multiple Acquisitionshttps://modernod.com/news/acuity-eyecare-group-enters-texas-market-with-multiple-acquisitions/2476785/Riata Capital Group announced that its portfolio company Acuity Eyecare Group, an owner and operator of North American eyecare groups and optometry practices, has acquired 11 regional eyecare practices in Texas. These acquisitions are the first for Acuity Eyecare
- SIFI Announces Expansion in the French Market With Acquisition of Dacudoses and Novoptinehttps://modernod.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/Italian ophthalmic company SIFI has announced the acquisition of Dacudoses and Novoptine antiseptic brands in France from Laboratoire Gifrer Barbezat. Terms of the deal were not disclosed. Dacudoses is the leading reimbursed RX brand of the French ophthalmic antiseptic segment, pres
- Ocular Science Launches Two Affiliates to Focus on Compounding and Biologic Sectors of Ophthalmic Markethttps://modernod.com/news/ocular-science-launches-two-affiliates-to-focus-on-compounding-and-biologic-sectors-of-ophthalmic-market/2476525/Ocular Science has divided its Southern California-based operation into two standalone C corporations: OSRX, Inc., the company’s 503A compounding pharmacy (formerly Pinnacle Compounding); and Regenerative Science, which commercializes biologics for the management of dry eye disease. According to
- Laser Vision Correction Market Growth Continues for Third Consecutive Yearhttps://modernod.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/US laser vision correction procedure volume grew for the third straight year in 2018, reflecting continued strong demand for LASIK and other forms of laser vision correction, according to figures released by The Refra
- Staar Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growthhttps://modernod.com/news/staar-surgical-expects-fourth-quarter-icl-sales-to-rise-42-china-units-nearly-double-u-s-market-returns-to-growth/2476216/Staar Surgical, which provided preliminary sales results for the fourth quarter ending December 28, 2018, said it expects fourth quarter ICL net sales to increase approximately 42% over the prior year period. Total net sales for the fourth quarter are expected to be approximately $31.2 million an
- Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based OCT Closer to Markethttps://modernod.com/news/notal-vision-engages-wasatch-photonics-bringing-ai-enabled-home-based-oct-closer-to-market/2479605/Notal Vision has announced the achievement of a significant milestone in its plan to develop and commercialize a home-based, patient-operated, spectral-domain optical coherence tomography (SD-OCT) system. The first targeted application of the Notal Home OCT is to monitor wet age-related macular d
- Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese Markethttps://modernod.com/news/nicox-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-develop-and-commercialize-ncx-470-in-the-chinese-market/2479610/Nicox and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension
- IDx and Topcon Sign Exclusive AI Platform Agreement For the U.S. Markethttps://modernod.com/news/idx-and-topcon-sign-exclusive-ai-platform-agreement-for-the-u-s-market/2479766/AI diagnostics company IDx and Topcon have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the United States. Terms of the deal were not disclosed. The agreement grants exclusive rights to IDx in the US as the only